Pharmacy Value Models

Pharmacy value models are shifting from medication dispensing economics toward reimbursable access, adherence, and clinical-integration infrastructure: enrollment has opened for the ACCESS to Pharmacy Care Program, while pharmacies are investing in revenue-cycle capabilities to bill for clinical services—an important step if ACOs, MA plans, and Medicaid managed care organizations want pharmacy teams tied to outcomes rather than spread/PBM margin alone (ACCESS to Pharmacy Care Program). At the same time, Amazon Pharmacy’s $50 GLP-1 delivery for Medicare Bridge Program beneficiaries and Humana’s pharmacy-care study signal payer and retailer positioning around high-cost chronic therapies, adherence, and member retention, creating new competitive pressure on traditional pharmacy networks and PBM-mediated care models. The strategic tension for VBC stakeholders is that adherence, rural pharmacy access, SDOH, and specialty-drug coordination are increasingly measurable levers for total cost and quality, but current adherence metrics remain contested and may need redesign before pharmacy performance can be reliably embedded in shared-savings or risk contracts ([adherence metrics scrutiny](https://news.google.com/rss/articles/CBMi1gFBVV95cUxPQXR2ckZTMDFONmJwazg0WEQwRWlCVjNTVVNxdnpBd2QtY0tJWE4tdlBNZXNVSjU4T0tCRTZPUS